AIV Logo AIV Assistant

Loading...

 Logo Fortress Biotech, Inc. - FBIOP 8.36 USD

EPS
-0.86
Yield
29.67%
P/B
4.47
ROE
-1739.64
Beta
1.73

8.360 USD

8.360 USD

Daily: +0.00%
Key Metrics

EPS: -0.86

Book Value: 1.49

Price to Book: 4.47

Debt/Equity: 5582.36

Growth

Revenue Growth: 0.05%

Dividend

Dividend Yield: 29.67%

Annual dividends: 2.34 USD

Ex-Div. Date: June 14, 2024

Payout: -6.54%

5y avg Yield: 14.61%

 Logo About Fortress Biotech, Inc. - (FBIOP)

Country: United States

Sector: Health Care

Website: http://www.fortressbiotech.com

Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

Exchange Ticker
NMS (United States) FBIOP
Dividend Yield

29.67% (5y avg: 14.61%)

Annual Dividends

2.34 USD

Next ex. div date

June 14, 2024

Payout Ratio

-6.54%

Historical Dividends
Year Total Dividends
2024 1.17 USD
2023 2.34 USD
2022 2.34 USD
2021 2.34 USD
2020 2.34 USD
2019 2.34 USD
2018 2.34 USD

Yearly aggregated dividends

Dividends

Historical Split Corporate Actions

Trades
My Trades
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion